Simbrinza Brinzolamide 1% and Brimonidine Tartrate 0.2% Eye Drops – 5ml

Simbrinza Eye Drops 5ml contain brinzolamide 1% and brimonidine tartrate 0.2% to reduce elevated intraocular pressure in adults with open-angle glaucoma or ocular hypertension. Prescription required.

 more information

SAR 64.60

+  

Earn loyalty points with this purchase

Rewards  

product sku

Z.17950970463002172

Weight

 kg

Quantity

This product is out of stock

Notify me when product is available

share product

product description

Simbrinza Brinzolamide 1% and Brimonidine Tartrate 0.2% Eye Drops Suspension – 5ml

Simbrinza is a prescription ophthalmic medicine combining brinzolamide 1% and brimonidine tartrate 0.2%. It is indicated for reducing elevated intraocular pressure in adults with open-angle glaucoma or ocular hypertension when treatment with a single agent is insufficient.

Marketed by Novartis Pharma, Simbrinza is supplied as an ophthalmic suspension in a 5ml dropper bottle.

Indications and Uses

  • Management of elevated intraocular pressure in adults.
  • Treatment of open-angle glaucoma.
  • Management of ocular hypertension when monotherapy is insufficient.
  • Reduction of pressure-related risks to the optic nerve through appropriate intraocular pressure control.

Active Ingredients

Brinzolamide – 10mg/ml (1%)

A carbonic anhydrase inhibitor that reduces aqueous humor production within the eye.

Brimonidine Tartrate – 2mg/ml (0.2%)

An alpha-2 adrenergic receptor agonist that contributes to lowering intraocular pressure.

How Does Simbrinza Work?

The two active ingredients reduce aqueous humor production through different pharmacological mechanisms, helping lower pressure within the eye.

Regular ophthalmological examinations are necessary to assess treatment response.

Simbrinza for Open-Angle Glaucoma

Glaucoma is an eye condition associated with progressive optic nerve damage that may result in irreversible visual field loss.

Managing intraocular pressure helps reduce the risk of disease progression. Simbrinza does not restore vision already lost through optic nerve damage.

Simbrinza for Ocular Hypertension

Elevated intraocular pressure may occur without noticeable symptoms.

Patients should continue their prescribed treatment and attend regular eye examinations even if they feel well.

Directions for Use

The usual European prescribing regimen is one drop into each affected eye twice daily, or as directed by an ophthalmologist.

Wash your hands and shake the bottle thoroughly before administration. Tilt your head backward and gently pull down the lower eyelid before applying one drop.

Avoid touching the eye or surrounding surfaces with the dropper tip.

Close the eye and gently press the inner corner near the nose for two minutes to help reduce systemic absorption.

Allow at least five minutes between different ophthalmic medications.

If a dose is missed, continue with the next scheduled dose. Do not double the dose.

Contact Lens Precautions

Simbrinza contains benzalkonium chloride as a preservative. Remove contact lenses before application and wait at least 15 minutes before reinserting them.

Contraindications

Do not use in patients with hypersensitivity to brinzolamide, brimonidine, sulfonamides or other formulation ingredients.

The medicine is contraindicated in severe renal impairment, hyperchloremic acidosis and patients taking MAO inhibitors or certain antidepressants.

It must not be used in children younger than two years and is not recommended for individuals under 18 years of age.

Warnings and Drug Interactions

Inform your doctor if you have cardiovascular disease, liver or kidney impairment, low blood pressure, circulatory disorders or corneal problems.

Potential interactions include certain antihypertensive medicines, sedatives, antidepressants and oral carbonic anhydrase inhibitors such as acetazolamide.

Simbrinza is not recommended during pregnancy and should not be used during breastfeeding according to the reference prescribing information.

Possible Side Effects

Potential adverse effects include eye redness, irritation, temporary blurred vision, bitter taste, dry mouth and drowsiness.

Avoid driving if your vision or alertness is affected.

Seek urgent medical attention if serious allergic reactions, blistering skin reactions, facial swelling or breathing difficulties occur.

Sudden severe eye pain with deterioration of vision also requires urgent medical assessment.

Product Specifications

Brand: Simbrinza.

Active Ingredients: Brinzolamide 1% and Brimonidine Tartrate 0.2%.

Dosage Form: Ophthalmic Suspension.

Marketing Company: Novartis Pharma.

Manufacturer: Alcon Couvreur.

Country of Manufacture: Belgium.

Pack Size: 5ml.

SFDA Registration Number: 2505233729.

Legal Status: Prescription Medicine.

Storage Instructions

Store below 30°C according to the Saudi registration information and follow the instructions on the actual package.

Discard the bottle 28 days after opening according to the reference patient leaflet.

Protect from excessive heat and keep out of reach of children.

Frequently Asked Questions

Does Simbrinza contain corticosteroids?

No. Its active ingredients are brinzolamide and brimonidine tartrate.

Does Simbrinza treat cataracts?

No. It is intended to reduce intraocular pressure rather than treat cataracts.

Should Simbrinza be shaken before use?

Yes. It is an ophthalmic suspension.

Can Simbrinza be discontinued when eye pressure improves?

Do not discontinue treatment or adjust the dose without consulting your ophthalmologist.

Does Simbrinza require a prescription?

Yes. A valid medical prescription is required.

Simbrinza at Al Jafen Pharmacy

Simbrinza Brinzolamide 1% and Brimonidine Tartrate 0.2% Eye Drops 5ml is classified under prescription ophthalmic medicines at Al Jafen Pharmacy.

Dispensing is subject to prescription verification and professional pharmacist review.

Reviews
(0)
  Add Comment

0.0

0     Great
0     Excellent
0     Good
0     Dislike
0     Bad
No reviews, add yours
Questions
You may also like